IHC - CA125

IHC – CA125 Test

The IHC CA125 Test is a specialized immunohistochemistry (IHC) diagnostic test used to detect CA125 (Cancer Antigen 125) protein expression in tissue samples. CA125 is an important tumor-associated glycoprotein commonly expressed in ovarian epithelial tumors, certain gynecological cancers, and selected non-gynecological malignancies.

This test plays a critical role in tumor classification, ovarian cancer diagnosis, and differential diagnosis of epithelial malignancies. It helps pathologists determine whether tumor cells express CA125 protein, which supports identifying tumor origin and confirming specific cancer subtypes.

The IHC CA125 test is commonly used in evaluating:

• Ovarian epithelial carcinoma
• Serous ovarian tumors
• Endometrial carcinoma
• Peritoneal carcinoma
• Metastatic adenocarcinoma differentiation

The test is performed on FFPE (Formalin-Fixed Paraffin-Embedded) tissue biopsy or surgical specimens using advanced antibody staining methods. Expert pathologists examine stained tissue under a microscope to assess CA125 expression patterns and support accurate diagnosis.

This test is particularly valuable when routine histopathology findings are inconclusive or when distinguishing between primary ovarian tumors and metastatic lesions is essential.

Accurate CA125 tissue expression analysis helps oncologists determine prognosis, guide treatment decisions, and support personalized oncology care.

Benefits of the Test

• Detects CA125 protein expression accurately
• Supports ovarian tumor diagnosis
• Helps identify tumor origin
• Assists cancer subtype classification
• Improves pathology diagnostic precision
• Supports personalized treatment planning

Why Doctors Recommend This Test

Doctors commonly recommend the CA125 IHC Test when:

• Ovarian tumor is suspected
• Tumor origin requires clarification
• Histopathology findings are inconclusive
• Differential diagnosis is necessary
• Gynecological cancer classification is required
• Metastatic tumor source evaluation is needed
• Personalized treatment planning depends on exact diagnosis
• Advanced oncopathology confirmation is required

This test improves diagnostic confidence for accurate cancer management.

Preparation Before the Test

Preparation usually includes:

• Submission of FFPE tissue block or unstained slides
• Previous pathology reports
• Relevant imaging and clinical records
• Proper specimen labeling and packaging
• Laboratory authorization documentation

No fasting or direct patient preparation is required.

Normal Reporting Time

The normal reporting time for the CA125 IHC Test is usually 4–7 working days, depending on staining complexity and expert interpretation requirements.

Who Should Take This Test?

This test is recommended for:

• Patients with suspected ovarian tumors
• Individuals requiring tumor origin identification
• Patients undergoing gynecologic cancer evaluation
• Individuals with unclear tissue diagnosis
• Oncology patients under specialist care
• Patients requiring advanced immunohistochemistry confirmation

At Focus Diagnostics Hyderabad, advanced immunohistochemistry technology and expert oncopathology specialists ensure highly accurate CA125 IHC reports for reliable diagnosis and personalized cancer treatment planning.